Literature DB >> 24854794

Diversification in the Supply Chain of (99)Mo Ensures a Future for (99m)Tc.

Cathy S Cutler1, Sally W Schwarz2.   

Abstract

The uncertain availability of (99m)Tc has become a concern for nuclear medicine departments across the globe. An issue for the United States is that currently it is dependent on a supply of (99m)Tc (from (99)Mo) that is derived solely by production outside the United States. Since the United States uses half the world's (99)Mo production, the U.S. (99)Mo supply chain would be greatly enhanced if a producer were located within the United States. The fragility of the old (99)Mo supply chain is being addressed as new facilities are constructed and new processes are developed to produce (99)Mo without highly enriched uranium. The conversion to low-enriched uranium is necessary to minimize the potential misuse of highly enriched uranium in the world for nonpeaceful means. New production facilities, new methods for the production of (99)Mo, and a new generator elution system for the supply of (99m)Tc are currently being pursued. The progress made in all these areas will be discussed, as they all highlight the need to embrace diversity to ensure that we have a robust and reliable supply of (99m)Tc in the future.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  99mTc generator; CMS reimbursement; HEU; LEU; novel 99Mo production

Mesh:

Substances:

Year:  2014        PMID: 24854794     DOI: 10.2967/jnumed.113.131953

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  2 in total

1.  Altered [99mTc]Tc-MDP biodistribution from neutron activation sourced 99Mo.

Authors:  Sandor Demeter; Roman Szweda; Judy Patterson; Marine Grigoryan
Journal:  J Radioanal Nucl Chem       Date:  2018-03-29       Impact factor: 1.371

2.  Nuclear medicine services after COVID-19: gearing up back to normality.

Authors:  H L Huang; G Gnanasegaran; D Paez; S Fanti; M Hacker; M Sathekge; H S Bom; J J Cerci; A Chiti; X Lan; K Herrmann; A M Scott; S Vinjamuri; S Dorbala; E Estrada; O Pellet; P Orellana; N El-Haj; F Giammarile; M Abdel-Wahab; Jamshed Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.